Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study

BACKGROUND: On September 5, 2019, British Columbia announced a new policy (the Biosimilars Initiative) to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases. OBJECTIVE: To monitor the impacts of the policy on the use of medications and health services durin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Anat, Kim, Jason D., Dormuth, Colin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995207/
https://www.ncbi.nlm.nih.gov/pubmed/36911254
http://dx.doi.org/10.1155/2023/2794220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995207/
https://www.ncbi.nlm.nih.gov/pubmed/36911254
http://dx.doi.org/10.1155/2023/2794220

Ejemplares similares